Quetiapine treatment and improved cognitive functioning in borderline personality disorder

Human Psychopharmacology

Volumn 24, Issue 8, 2009, Pages 646-649

  Van Den Eynde, Frederique ^a,b,c   De Saedeleer, Sofie ^a   Naudts, Kris ^b   Day, Jemma ^b   Vogels, Caroline ^c   Van Heeringen, Cornelis ^a   Audenaert, Kurt ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c St Camillus Psychiatric Hospital   (Belgium)

Author keywords

Borderline personality disorder; Cognitive functioning; Executive functions; Quetiapine

Indexed keywords

QUETIAPINE;

ACCURACY; ADULT; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PHONETICS; PRIORITY JOURNAL; SCORING SYSTEM; SEMANTICS; TASK PERFORMANCE; TOWER OF LONDON TASK; TRAIL MAKING TASK; TREATMENT DURATION; TREATMENT RESPONSE; WORD FLUENCY TASK;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; COGNITION DISORDERS; DIBENZOTHIAZEPINES; EXECUTIVE FUNCTION; FEMALE; HUMANS; LINEAR MODELS; MALE; NEUROPSYCHOLOGICAL TESTS; YOUNG ADULT;

EID: 73449086967     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1075     Document Type: Article

References (26)

1. American Psychiatric Association. 2001. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158: 1-52.
2. Arntz A, Appels C, Sieswerda S. 2000. Hypervigilance in borderline disorder: a test with the emotional Stroop paradigm. J Pers Disord 14: 366-373.
3. Berg K, Byrd D. 2002. The Tower of London spatial problem-solving task: enhancing clinical and research implementation. J Clin Exp Neuropsychol 24: 586-604.
4. Binks CA, Fenton M, McCarthy L, Lee T, Adams CE, Duggan C. 2006. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev 25 (1): Art. No.: CD005653.
5. Bosanac P, Kurlender S, Norman T, et al. 2007. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol Clin Exp 22: 223-230.
6. Cheer SM, Wagstaff AJ. 2004. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18: 173-199.
7. de Geus F, Denys D, Westenberg HG. 2007. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol 22: 77-84.
8. Dinn WM, Harris CL, Aycicegi A, Greene PB, Kirkley SM, Reilly C. 2004. Neurocognitive function in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 28: 329-341.
9. Fertuck EA, Lenzenweger MF, Clarkin JF, Hoermann S, Stanley B. 2006. Executive neurocognition, memory systems, and borderline personality disorder. Clin Psychol Rev 26: 346-375.
10. Gueorguieva R, Krystal J. 2004. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61: 310-317.
11. Harvey PD, Patterson TL, Potter LS, Zhong K, Brecher M. 2006. Improvement in social competence with short term atypical antipsychotic treatment: a randomized double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 163: 1918-1925.
12. Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. 2007. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. J Clin Psychiatry 68: 1186-1194.
13. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ. 2007. WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 8: 212-244.
14. Keefe RS, Silva SG, Perkins DO, Lieberman JA. 1999. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201-222.
15. Kunert HJ, Druecke HW, Sass H, Herpertz SC. 2003. Frontal lobe dysfunctions in borderline personality disorder? Neurpsychological findings. J Pers Disord 17: 497-509.
16. New AS, Triebwasser J, Charney DS. 2008. The case for shifting borderline personality disorder to axis I. Biol Psychiatry 64: 653-659.
17. Nosé M, Cipriani A, Biancosino B, Grassi L, Barbui C. 2006. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 21: 345-353.
18. Posner MI, Rothbart MK, Vizueta N, et al. 2002. Attentional mechanisms of borderline personality disorder. Proc Natl Acad Sci USA 99: 16366-16370.
19. Reitan RM. 1955. The relation of the trail making test to organic brain damage. J Consult Psychol 19: 393-394.
20. Shallice T. 1982. Specific impairments of planning. Philos Trans R Soc Lond 298: 199-209.
21. Siever LJ, Davis KL. 1991. A psychobiological perspective on the personality disorders. Am J Psychiatry 148: 1647-1658.
22. Sprock J, Rader TJ, Kendall JP, Yoder CY. 2000. Neuropsychological functioning in patients with borderline personality disorder. J Clin Psychol 56: 1587-1600.
23. Van den Eynde F, Senturk V, Naudts K, et al. 2008. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 28: 147-155.
24. Van Reekum R, Conway CA, Gansler D, White R, Bachman DL. 1993. Neurobehavioral study of borderline personality disorder. J Psychiatry Neurosci 18: 121-129.
25. Van Reekum R, Links PS, FinlaysonMA, et al. 1996. Repeat neurobehavioral study of borderline personality disorder. J Psychiatry Neurosci 21: 13-20.
26. Voruganti LP, Awad AG, Parker G, et al. 2007. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 96: 146-155.